A joint project of the Graduate School, Peabody College, and the Jean & Alexander Heard Library

Title page for ETD etd-03222017-135307

Type of Document Dissertation
Author Nyhoff, Lindsay Elizabeth
URN etd-03222017-135307
Title Bruton's typrosine kinase and autoreactive B lymphocytes: Roles in development, survival, and disease
Degree PhD
Department Microbiology and Immunology
Advisory Committee
Advisor Name Title
Amy S. Major Committee Chair
Anne K. Kenworthy Committee Member
James W. Thomas Committee Member
Luc Van Kaer Committee Member
Peggy L. Kendall Committee Member
  • B cell receptor
  • K/BxN
  • B-1a
  • B-1b
Date of Defense 2017-03-13
Availability unrestricted
Bruton’s tyrosine kinase (BTK) is a tec-family kinase present in B lymphocytes and innate immune cells. BTK is an important regulator of B cell autoreactivity. Innate-like autoreactive-prone B1, anergic An1, and transgenic anti-insulin B cells all rely upon BTK. Autoreactive B cells drive Type 1 diabetes (T1D) development and are preferentially targeted by disruption of BTK. We hypothesized that the same strategy could be extended to systemic autoimmunity, typified by rheumatoid arthritis (RA). We found that genetic deletion of BTK in a model of spontaneous arthritis results in a severe block in B cell development, subsequent reduction of germinal center formation and reduced autoantibody production, culminating in disease protection. In contrast, the development of immune-complex mediated arthritis, which relies upon the innate immune system, was not alleviated by genetic deletion of BTK. We have well established that BTK-deficiency results in loss of autoreactive B cells; however, whether these cells require BTK for maturation only, or also for their survival, remained unknown. Our group has developed the first loxP-flanked Btk mouse model, paired with an inducible Cre-ERT2 for kinetic studies of BTK function. We achieve 90% knockdown within five days after tamoxifen-induced Cre activation. We find that the B cell phenotype typical of murine Btk-deficiency emerges quickly, including a developmental block at T2, and decreased follicular B cells. Surprisingly, B1 B cells are not reduced, in contrast to their near-absence in Btk-deficient models. BTK-negative B1 cells remain able to produce natural IgM, but cannot respond to T-independent immunization. Furthermore, transgenic anergic anti-insulin B cells, which are reduced 95% by conventional Btk-deficiency, also maintain large mature populations after deletion of Btk protein, and remain able to internalize insulin. These findings suggest that autoimmune-prone B cell populations require BTK-mediated signaling for development, but not for survival or certain functions, and may have implications for the use of BTK-inhibitors currently in clinical trials for treatment of autoimmunity.
  Filename       Size       Approximate Download Time (Hours:Minutes:Seconds) 
 28.8 Modem   56K Modem   ISDN (64 Kb)   ISDN (128 Kb)   Higher-speed Access 
  Dissertation_LindsayNyhoff_ETD.pdf 3.96 Mb 00:18:19 00:09:25 00:08:14 00:04:07 00:00:21

Browse All Available ETDs by ( Author | Department )

If you have more questions or technical problems, please Contact LITS.